UBS Group
SKYE icon

UBS Group’s Skye Bioscience SKYE Stock Holding History

UBS Group’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.1K Buy
9,225
+3,505
+61% +$22K ﹤0.01% 7550
2026
Q1 		$28.1K Buy
5,720
+4,059
+244% +$26.5K ﹤0.01% 7731
2025
Q4 		$9.96K Sell
1,661
-2,088
-56% -$24.4K ﹤0.01% 8252
2025
Q3 		$118K Sell
3,749
-1,441
-28% -$43.5K ﹤0.01% 7005
2025
Q2 		$174K Sell
5,190
-13,759
-73% -$228K ﹤0.01% 6815
2025
Q1 		$241K Buy
18,949
+11,502
+154% +$251K ﹤0.01% 6417
2024
Q4 		$169K Buy
7,447
+4,202
+129% +$140K ﹤0.01% 6558
2024
Q3 		$101K Buy
3,245
+2,589
+395% +$116K ﹤0.01% 6357
2024
Q2 		$42.1K Buy
+656
New +$62.3K ﹤0.01% 6828

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's SKYE Position: Q2 2026 in Review

UBS Group increased its Skye Bioscience (SKYE) stake by 61% in Q2 2026, buying an estimated $22K and bringing the position to 9,225 shares worth $51.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7550.

UBS Group first reported a position in SKYE in Q2 2024 and has held it in 9 quarters since. The position peaked at $241K in Q1 2025. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • UBS Group held 9,225 shares of Skye Bioscience worth $51.1K as of Q2 2026.
  • UBS Group bought 3,505 Skye Bioscience shares in Q2 2026, an estimated $22K.
  • Skye Bioscience made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7550 holding.
  • UBS Group first reported a position in Skye Bioscience in Q2 2024 and has held it in 9 quarters since.
  • UBS Group's Skye Bioscience position peaked at $241K in Q1 2025.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.